Oncology Radiopharmaceutical innovation: Giving cancer drugs second c... Molecular recycling could transform the economics and innovation of oncology drug discovery.
Oncology ESMO25: On radiopharmaceutical possibilities in oncology, wi... At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.
Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
News Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
News Radiopharma CDMO Nucleus names former FDA boss as CEO CDMO Nucleus RadioPharma has a high-profile new CEO: former FDA Commissioner and veteran cancer researcher Dr Stephen Hahn.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
